A diagnosis of acute lymphoblastic leukemia (ALL) can bring many questions and uncertainties. During the Know ALL Ambassador Meeting, Jaymz Goodman, Jessica Olson, Lidija Pecova, Sharon Cohan, and Yusuf Adelabu answered key questions raised within the acute lymphoblastic leukemia community, ranging from common misconceptions at diagnosis to peer support and clinical trials. The questions discussed are summarized here.
What are the common misconceptions patients have about acute lymphoblastic leukemia at diagnosis?
Many people search online after diagnosis, but the information they find may be out of date or may not reflect recent advances in treatment. It is important to understand that acute lymphoblastic leukemia is not a single disease and that treatment and outcomes can vary.
Why is measurable residual disease testing helpful?
Measurable residual disease (MRD) testing can provide important information about how well treatment is working and may help guide further treatment decisions. Measurable residual disease negativity different from remission, and taking time to explain what measurable residual disease means can help patients feel more informed about their care.
What support do patients find particularly helpful (e.g., peer support groups, counseling)?
Peer support can help patients connect with others going through similar experiences, reduce feelings of isolation, and provide practical advice and reassurance. Counseling and support from patient organizations can also be valuable, although access varies between countries and communities.
How can patients prepare for appointments?
When appointments are short and there is a lot to discuss, preparing questions in advance can help. It can be helpful to identify the three most important questions before each appointment. Patient resources and support from people with similar experiences can also help patients feel more prepared.
How do caregiving responsibilities shift over the course of the disease journey?
Caregivers can play an important role throughout the acute lymphoblastic leukemia journey, from helping with appointments and treatment decisions to providing emotional and practical support. It is important to recognizing caregivers’ own needs and ensure they have access to appropriate information and support.
What are the risks and benefits of joining a clinical trial?
Clinical trials can provide access to new treatments and closer monitoring, while also helping improve care for patients in the future. However, travel, costs, and uncertainty about treatment and potential side effects can present challenges. Understanding the potential benefits and risks can help patients make informed decisions.
Overall, the ambassadors highlighted the importance of clear information, effective communication, and appropriate support throughout the acute lymphoblastic leukemia journey, helping patients and caregivers feel informed and supported.
This educational resource is independently supported through funding from pharmaceutical companies. A full list of our current funders can be found on our website. All content is developed by SES in collaboration with an expert ambassador group. Funders are allowed no influence.
